News
Tag: Company Updates
-
Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer
Donnelly brings more than 25 years of biopharmaceutical expertise in CMC and regulatory operations. SEATTLE and VANCOUVER, British Columbia, September 18, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced…
-
Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer
SEATTLE and VANCOUVER, British Columbia, September 11, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced Mark Rubinstein, M.D., will assume the role of Interim Chief Medical Officer (CMO). Dr….
-
Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades
Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy. Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical public health need. Seattle and Vancouver, British Columbia, June 26, 2025 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company…
-
Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors
New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization. SEATTLE and VANCOUVER, British Columbia – January 10, 2025 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Kristen Slaoui, Ph.D., and Nancy Phelan…
-
Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer
SEATTLE and VANCOUVER, British Columbia, December 9, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Mark Oki has joined the company as its Chief Financial Officer, effective December 5, 2024. Mr….